Ligament InjuryPhase 4CALFNCT02667730
Correlation Between Acute Analgesia and Long-Term Function Following Ankle Injuries
A Phase 4 study testing Acetaminophen, Naproxen and Celecoxib in people with Ligament Injury, run by Canadian Department of National Defence at 1 site in Canada.
Trial summary
In this 4-arm pragmatic randomized control trial, the investigators hope to decipher whether the use of non-opioid analgesics (naproxen, celecoxib, acetaminophen) in addition to standardized physiotherapy during the acute phase of grade I-II ankle injuries will result in functional differences compared to standardized… Read more about this study
- Who is it for?
- Ages 17 to 60 years
- Conditions the study is for
- Ligament Injury
- What is being tested?
- Acetaminophen, Naproxen and Celecoxib
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 168 participants
- Where
- 1 siteCanada
- Study dates
- Jun 2015to Dec 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 to 60 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Acquired acute ankle injury (injured less than 48 hours ago);
- Clinical diagnosis of a Grade I or II ankle sprain
- Is eligible to receive comprehensive medical care from Garrison Petawawa
Who cannot join
- Diagnosis of ankle fracture or ligament rupture
- Has planned release from the Canadian Armed Forces within one year;
- Documented restrictions on military duties
- Has known intolerance or documented adverse reaction to acetaminophen or naproxen or celecoxib
- Documented history of liver or kidney problems
- pregnant or breastfeeding
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Correlation Between Acute Analgesia and Long-Term Function Following Ankle
In this 4-arm pragmatic randomized control trial, the investigators hope to decipher whether the use of non-opioid analgesics (naproxen, celecoxib, acetaminophen) in addition to standardized physiotherapy during the acute phase of grade I-II ankle injuries will result in functional differences compared to standardized physiotherapy alone
Read the detailed description
Background Ankle sprains occur frequently in the Canadian Armed Forces (CAF) population and account for a significant proportion of lost work time. Equally significant is the use of analgesics (NSAID or non-NSAID) (NSAID = non steroidal anti-inflammatory drug) in the CAF population. Existing literature suggests that the rate and extent of soft tissue healing may be adversely affected by use of some analgesics, particularly non-steroidal anti-inflammatory agents (NSAIDs), when these are used immediately following joint injury. There have been two postulated mechanisms for this observation: the first being that inflammatory markers are required in the regeneration process; the second is that the diminished pain level as a result of analgesic use encourages overuse of the injured tissue. Unfortunately, the science is far from conclusive, since much of it is derived based on isolated exercises, conducted in experimental settings, in older populations, or extrapolated from biomarkers that have not been validated for clinical relevance. While there is no current standard of practice regarding the use of pain relievers following ankle injury, this practice continues to be widespread in the CAF.
Goal The proposed study aims to clarify whether three commonly used non-opioid pain relievers provide additional benefit or delay improvement in ankle function following mild ankle sprains, when compared to standardized physiotherapy treatment alone. The three agents investigated will be 1) the non-steroid anti-inflammatory drug naproxen, 2) the selective anti-inflammatory celecoxib, and 3) the centrally-acting analgesic acetaminophen.
Methods Patients presenting to the health clinic at Garrison Petawawa with acute ankle injuries will be screened for study eligibility. All individuals who elect to participate in this study will be referred for standardized physiotherapy treatment, which will be administered according to study protocol. Participants will also be randomized to one of four analgesic treatment groups (i.e., naproxen, celecoxib, acetaminophen, or non-pharmacological measures only), with stratification for grade of ankle injury. Physiotherapists who are blinded to analgesic treatment allocation will evaluate participants' ankle function at 72 hours, 2 weeks, 3 months and 1 year post-injury, using previously validated tests. Pharmacists will assess response to drug therapy, side effects, and use of rescue medications at day 7 following enrollment. Occurrence of repeat ankle injuries and health resource consumption (i.e., specialist visits and diagnostic imaging) will also be assessed for the year following index injury.
Risks This study is intended to be low risk to participants as it is designed to closely mirror existing practices for such injuries. All medications used in this study are indicated for soft tissue injuries and their respective dosages/frequencies/durations aligned with manufacturer recommendations. The physiotherapy intervention was developed by Dr. Eric Robitaille. It has been used in previous studies and is currently in use in the CAF. The investigators do not expect the risk of injury to be higher than that associated with existing practices for ankle injuries.
Benefits Participants are expected to benefit from the direct application of a standardized physiotherapy treatment protocol for overall management of their condition as well as the pain relief from the analgesic options. The results of this study are expected to generate new information that can be readily applied to patient care, specifically in treating a frequently-occurring soft tissue injury in the CAF population.
- Conditions
- Ligament Injury
- Being tested
- Acetaminophen, Naproxen, Celecoxib, physiotherapy only
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AcetaminophenDrug
Also called tylenol
Acetaminophen 500 mg four times daily for 7 days
NaproxenDrug
naproxen 500mg twice daily for 7 days
CelecoxibDrug
Also called celebrex
celecoxib 100mg twice daily
physiotherapy onlyOther
physiotherapy only (no drug)
| Study group | Role | What they receive |
|---|---|---|
| Physiotherapy only | Placebo comparator | This group will receive non-pharmacological advice and physiotherapy only Receives: Other: physiotherapy only |
| Acetaminophen + physiotherapy | Experimental | This group will receive acetaminophen 500mg 4 times daily for 7 days in addition to standardized physiotherapy Receives: Drug: Acetaminophen; Other: physiotherapy only |
| Naproxen + physiotherapy | Experimental | This group will receive naproxen 500mg twice daily for 7 days in addition to standardized physiotherapy Receives: Drug: Naproxen; Other: physiotherapy only |
| Celecoxib + physiotherapy | Experimental | This group will receive celecoxib 100mg twice daily for 7 days in addition to standardized physiotherapy Receives: Drug: Celecoxib; Other: physiotherapy only |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ankle Function on FAAM
Foot and Ankle Abilities Measure
Measured: 3 months
Secondary outcomes (5)
Pain on visual analogue scale (VAS)
visual analogue scale
Measured: 3 months
Mobility on Wall Lunge
wall lunge test for ankle mobility
Measured: 3 months
Laxity on anterior drawer test
test for laxity
Measured: 3 months
Proprioception on SEBT
star excursion balance test
Measured: 3 months
composite of health resource consumption
# of orthopedic specialist consults, diagnostics, patient encounters for MSK reasons, # of days off work
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2016 (estimated)
- Study startJun 2015
- Primary completionMay 2019
- Study completionDec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ligament InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Care provider, Outcomes assessor
- Enrolment
- 168 participants (actual)
Sponsor and investigators
- Lead sponsor
- Canadian Department of National Defence
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Koren Lui, BScPHM, Principal investigator, Canadian Forces Health Services Group
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02667730
- Sponsor's protocol ID
- 2013-12-126-004-0001
- Acronym
- CALF
- Status last verified
- Feb 2024
- First submitted
- 9 Jul 2015
- Last updated
- 12 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation Between Acute Analgesia and Long-Term Function Following Ankle
- ClinicalTrials.gov ID
- NCT02667730
- Acronym / sponsor ID
- CALF / 2013-12-126-004-0001
- Conditions
- Ligament Injury
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 168 participants (actual)
- Lead sponsor
- Canadian Department of National DefenceOther government
- Study start
- Jun 2015 (actual)
- Primary completion
- May 2019 (actual)
- Study completion
- Dec 2021 (actual)
- First posted
- 29 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this 4-arm pragmatic randomized control trial, the investigators hope to decipher whether the use of non-opioid analgesics (naproxen, celecoxib, acetaminophen) in addition to standardized physiotherapy during the acute phase of grade I-II ankle injuries will result in functional differences compared to standardized physiotherapy alone
Detailed description
Background Ankle sprains occur frequently in the Canadian Armed Forces (CAF) population and account for a significant proportion of lost work time. Equally significant is the use of analgesics (NSAID or non-NSAID) (NSAID = non steroidal anti-inflammatory drug) in the CAF population. Existing literature suggests that the rate and extent of soft tissue healing may be adversely affected by use of some analgesics, particularly non-steroidal anti-inflammatory agents (NSAIDs), when these are used immediately following joint injury. There have been two postulated mechanisms for this observation: the first being that inflammatory markers are required in the regeneration process; the second is that the diminished pain level as a result of analgesic use encourages overuse of the injured tissue. Unfortunately, the science is far from conclusive, since much of it is derived based on isolated exercises, conducted in experimental settings, in older populations, or extrapolated from biomarkers that have not been validated for clinical relevance. While there is no current standard of practice regarding the use of pain relievers following ankle injury, this practice continues to be widespread in the CAF.
Goal The proposed study aims to clarify whether three commonly used non-opioid pain relievers provide additional benefit or delay improvement in ankle function following mild ankle sprains, when compared to standardized physiotherapy treatment alone. The three agents investigated will be 1) the non-steroid anti-inflammatory drug naproxen, 2) the selective anti-inflammatory celecoxib, and 3) the centrally-acting analgesic acetaminophen.
Methods Patients presenting to the health clinic at Garrison Petawawa with acute ankle injuries will be screened for study eligibility. All individuals who elect to participate in this study will be referred for standardized physiotherapy treatment, which will be administered according to study protocol. Participants will also be randomized to one of four analgesic treatment groups (i.e., naproxen, celecoxib, acetaminophen, or non-pharmacological measures only), with stratification for grade of ankle injury. Physiotherapists who are blinded to analgesic treatment allocation will evaluate participants' ankle function at 72 hours, 2 weeks, 3 months and 1 year post-injury, using previously validated tests. Pharmacists will assess response to drug therapy, side effects, and use of rescue medications at day 7 following enrollment. Occurrence of repeat ankle injuries and health resource consumption (i.e., specialist visits and diagnostic imaging) will also be assessed for the year following index injury.
Risks This study is intended to be low risk to participants as it is designed to closely mirror existing practices for such injuries. All medications used in this study are indicated for soft tissue injuries and their respective dosages/frequencies/durations aligned with manufacturer recommendations. The physiotherapy intervention was developed by Dr. Eric Robitaille. It has been used in previous studies and is currently in use in the CAF. The investigators do not expect the risk of injury to be higher than that associated with existing practices for ankle injuries.
Benefits Participants are expected to benefit from the direct application of a standardized physiotherapy treatment protocol for overall management of their condition as well as the pain relief from the analgesic options. The results of this study are expected to generate new information that can be readily applied to patient care, specifically in treating a frequently-occurring soft tissue injury in the CAF population.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Physiotherapy only | Placebo comparator | Other: physiotherapy onlyThis group will receive non-pharmacological advice and physiotherapy only |
| Acetaminophen + physiotherapy | Experimental | Drug: Acetaminophen, Other: physiotherapy onlyThis group will receive acetaminophen 500mg 4 times daily for 7 days in addition to standardized physiotherapy |
| Naproxen + physiotherapy | Experimental | Drug: Naproxen, Other: physiotherapy onlyThis group will receive naproxen 500mg twice daily for 7 days in addition to standardized physiotherapy |
| Celecoxib + physiotherapy | Experimental | Drug: Celecoxib, Other: physiotherapy onlyThis group will receive celecoxib 100mg twice daily for 7 days in addition to standardized physiotherapy |
Who may qualify
- Ages
- 17 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Acquired acute ankle injury (injured less than 48 hours ago);
- Clinical diagnosis of a Grade I or II ankle sprain
- Is eligible to receive comprehensive medical care from Garrison Petawawa
Key exclusion criteria (6 listed)
- Diagnosis of ankle fracture or ligament rupture
- Has planned release from the Canadian Armed Forces within one year;
- Documented restrictions on military duties
- Has known intolerance or documented adverse reaction to acetaminophen or naproxen or celecoxib
- Documented history of liver or kidney problems
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AcetaminophenAlso: tylenolAcetaminophen 500 mg four times daily for 7 days | Drug | Acetaminophen + physiotherapy |
| Naproxennaproxen 500mg twice daily for 7 days | Drug | Naproxen + physiotherapy |
| CelecoxibAlso: celebrexcelecoxib 100mg twice daily | Drug | Celecoxib + physiotherapy |
| physiotherapy onlyphysiotherapy only (no drug) | Other | Acetaminophen + physiotherapy, Celecoxib + physiotherapy, Naproxen + physiotherapy, Physiotherapy only |
Primary outcome
Ankle Function on FAAM
Time frame: 3 months
Foot and Ankle Abilities Measure
5 secondary outcomes
Pain on visual analogue scale (VAS)
Time frame: 3 months
Mobility on Wall Lunge
Time frame: 3 months
Laxity on anterior drawer test
Time frame: 3 months
Proprioception on SEBT
Time frame: 3 months
composite of health resource consumption
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2024.
- Individual participant dataSharing planned: No
Related trials for Ligament Injury
Not yet recruiting
Clinical and Biological Outcomes of BioBrace-Augmented ACL Reconstruction
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture
Not yet recruiting
Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Postoperative Recovery Quality in Patients Undergoing Anterior Cruciate Ligament Reconstruction
Anterior Cruciate Ligament Injuries, Recovery Quality
Not yet recruitingPhase 3
Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture
RecruitingObservational study
BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction Procedures
ACL Tears
Not yet recruiting
Correlation Between Soft Tissue Displacement and Functional Performance in Orthopedic Patients
Hamstring Muscle Strain, Adult Acquired Flatfoot Deformity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Koren Lui, BScPHM principal investigator
Canadian Forces Health Services Group
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Acetaminophen, Naproxen and Celecoxib in people with Ligament Injury, run by Canadian Department of National Defence at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ankle Function on FAAM (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2024.